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Patients with inflammatory bowel disease  (IBD) have 
an increased risk of developing intestinal cancer. The 
magnitude of that increased risk as well as how best to 
mitigate it remain a topic of ongoing investigation in 
the field. Although only 1% of all cases of colorectal 
cancer (CRC) occur in patients with ulcerative colitis (UC) 
or Crohn’s disease (CD), patients with IBD represent one 
of the highest risk groups for developing this dreaded 
complication.[1,2] A meta-analysis of 116 studies found 
the mean age of UC-CRC diagnosis to be 43.2 years.[3] 
Lakatos and coworkers[4] found the average age of IBD-CRC 
diagnosis to be 10-15 years younger than sporadic CRC in 
Eastern Europe (50.9 years vs. 62.2 years). The prognosis 
for sporadic CRC and IBD-CRC is similar, with a 5-year 
survival of approximately 50%.[5] Identifying at-risk patients 
and implementing appropriate surveillance for these 
patients is central to managing the CRC risk in IBD.[6]
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ABSTRACT
Patients with inflammatory bowel disease (IBD) have an increased risk of developing intestinal cancer. The 
magnitude of that increased risk as well as how best to mitigate it remain a topic of ongoing investigation 
in the field. It is important to quantify the risk of colorectal cancer in association with IBD. The reported 
risk varies widely between studies. This is partly due to the different methodologies used in the studies. 
Because of the limitations of surveillance strategies based on the detection of dysplasia, advanced endoscopic 
imaging and techniques involving the detection of alterations in mucosal antigens and genetic abnormalities 
are being investigated. Development of new biomarkers, predicting future occurrence of colonic neoplasia 
may lead to more biomarker-based surveillance. There are promising results that may lead to more efficient 
surveillance in IBD patients and more general acceptance of its use. A multidisciplinary approach, involving 
in particular endoscopists and pathologists, together with a centralized patient management, could help 
to optimize treatments and follow-up measures, both of which could help to reduce the IBD-associated 
cancer risk.
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It is important to quantify the risk of CRC in association with 
IBD. The reported risk varies widely between studies. This is 
partly due to the different methodologies used in the studies.
The aim of this review is to examine the magnitude of the 
risk of CRC in IBD patients, quantifying the risk factors, and 
especially to focus on the importance of surveillance for CRC 
in IBD patients, paying attention to the new techniques to 
detect early dysplasia and cancer.
MAGNITUDE OF RISK
Data about the magnitude of the risk of CRC in IBD patients 
come from tertiary referral centers, district general hospitals, 
and population-based studies. Information from tertiary 
centers is likely to regard patients with severe disease who 
are probably at greater risk of IBD-CRC.
The early studies included patients who had already been 
referred with a diagnosis of CRC and those admitted to 
hospital with IBD, rather than gold-standard population-based 
studies, which have a lower proportion of patients with severe 
or extensive colitis, which are per se adverse prognostic factors 
for increased risk of CRC. The increased risk of CRC in UC 
has long been established.
As mentioned above, a meta-analysis of 116 studies, 
performed by Eaden and coworkers, including overall 54,478 
UC patients, with 1698 cases of IBD-CRC, found an overall 
prevalence of CRC in UC of 3.7%, increasing to 5.4% in 
those with pancolitis. The analysis included studies from a 
wide variety of centers and from different geographical areas. 
Interestingly, the studies from the United Kingdom and the 
United States found a higher incidence [4 and 5 per 1000 
person-years duration (pyd), respectively] than those from 
Scandinavia (2 per 1000 pyd).[3]
A population-based cohort study performed by Ekbom and 
coworkers on 3117 patients with UC, who were diagnosed 
between 1922 and 1983, gave a standardized incidence 
ratio of 5.7  [95% confidence interval  (CI), 4.6-7.0] as 
compared with the expected incidence of CRC in the general 
population.[7] In another population-based study performed 
by Soderlund and coworkers on 7607 patients  with IBD who 
were diagnosed between 1954 and 1989, the standardized 
incidence ratio was 2.3 (95% CI, 2.0-2.6) as compared with 
the general population.[8] Other recent population-based 
studies have suggested a much lower risk of IBD-CRC.
In the study performed by Jess and coworkers on 
378 patients from Olmsted County with UC for a total 
of 5567 pyd (1940-2004), the annual crude incidence was 
found to be 0.10% and the cumulative risk of CRC at 
30 years proved to be as low as 2%. The authors concluded 
that the risk of CRC is only increased in patients with 
extensive colitis.[9]
Bernstein and coworkers obtained data about 2672 patients 
with UC between 1984 and 1997, and they found an annual 
risk of 0.16% for colon cancer and 0.06% for rectal cancer.[10]
The prospective study by Rutter and coworkers, performed 
on 600 patients with extensive UC for 5932 pyd as part of 
a colonoscopic surveillance program (1970-2001), found a 
cumulative probability of IBD-CRC of 7.6% and a decreasing 
incidence over the period studied.[11]
A Hungarian population-based study that followed 723 
UC patients  (1974-2004) calculated the cumulative risks 
according to disease duration: 0.6% after 10 years, 5.4% 
after 20 years, and 7.5% after 30 years, whereas Winther and 
coworkers[12] followed 1160 patients with UC (1962-1987) and 
gave an annual crude incidence of 0.06% and a cumulative 
risk of 2.1% at 30 years. However, this study is from Denmark, 
where the colectomy rate is one of the highest in the world, 
a fact that may affect the results and underestimate the risk 
of IBD-CRC, whereas Hungary has a high rate of sporadic 
CRC and a low rate of colectomy for non-CRC reasons; these 
factors may result in a higher rate of CRC.
More recently, another study performed by Jess and coworkers 
on CRC risk in a nationwide cohort of 47,374 Danish patients 
with IBD over a 30-year period, showed a low rate of CRC. 
For patients with UC, the overall relative risk (RR) for CRC 
decreased from 1.34 (95% CI, 1.13-1.58) in 1979-1988 to 
0.57 (95% CI, 0.41-0.80) in 1999-2008. Among patients with 
CD, the overall RR for CRC was 0.85 (95% CI, 0.67-1.07), 
which did not change over time. According to the authors, 
the decreasing risk for CRC from 1979 to 2008 might have 
resulted from improved therapies for patients with IBD.[13]
Interestingly, other studies have shown that Crohn’s colitis 
carries a similar magnitude of risk for the same disease extent. 
A Canadian cohort study matched a population-based IBD 
database to a cancer registry in North America between 1984 
and 1997, although a limitation of this study was the lack of 
definition of disease site or extent. There were 2857 cases 
of CD and 2672 of UC. There was an increased incidence 
of CRC for patients with Crohn’s [risk ratio (RR), 2.64; 
95% CI, 1.69-4.12] or UC (RR, 2.75; 95% CI, 1.91-3.97) 
as compared to the general population but no statistically 
significant difference between the two IBDs.[14] The authors 
of the study found the risk of rectal cancer to be increased 
in UC (RR, 1.90; 95% CI, 1.05-3.43) but not in Crohn’s 
colitis (RR, 1.08; 95% CI, 0.43-2.70).
Ekbom and coworkers also studied the risk of CRC in CD. 
In their cohort study of 1655 patients performed in Sweden, 
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patients with terminal ileal CD had the same risk of CRC 
as the general population but those with colonic CD had an 
RR of 5.6 (95% CI, 2.1-12.2).[15]
RISK FACTORS
Ulcerative colitis
Several factors have been identified that increase the risk 
of CRC in patients with UC, related to the disease and 
to the host. Among the former, the duration of disease 
is an important risk factor, as shown by the fact that the 
cumulative risk of cancer increases over time, as mentioned 
above.[3,7] Second, considering CRC risk as being associated 
with the cumulative effect of chronic inflammation, the 
extent of colon involvement in UC is an independent 
predictor of cancer risk.[7] In this connection, the study 
performed by Ekbom and coworkers showed that the RR 
of CRC was 1.7 for ulcerative proctitis, whereas the risk in 
left-sided colitis was 2.8 and this risk rose to 14.8 in patients 
with extensive colitis.[7] Third, considering the degree of 
mucosal inflammation, Rutter and coworkers demonstrated 
in their retrospective series that severity of inflammation on 
biopsy independently predicted risk of CRC.[16] This finding 
was supported by two other studies in which inflammatory 
activity was shown to be independently associated with CRC 
risk.[17,18] Additionally, it was also shown that backwash ileitis 
may be an independent predictor of increased CRC risk.[19]
With regard to the risk factors related to the host, a younger 
age at diagnosis is also associated with an elevated risk of 
CRC, independent of disease duration.[7] This may be 
because patients with an early age of diagnosis tend to 
have more severe inflammation.[16] Considering gender, 
Söderlund and coworkers[8] observed that the relative risk 
in males was 2.6 (95% CI, 2.2-3.1) and in females 1.9 (95% 
CI, 1.5-2.4) compared with the general population, whereas 
the cumulative incidence at 40  years after diagnosis of 
IBD was 8.3% in males and 3.5% in females. Similar results 
were found in a Swedish study performed by Ekbom and 
coworkers.[7]
Furthermore, a family history of CRC, independent of a 
family history of IBD, is associated with a higher risk of 
developing this neoplasia.[20-23] Finally, considering the 
comorbidity of UC patients, a meta-analysis by Soetikno 
and coworkers on the risk of CRC in UC patients with 
coexistent primary sclerosing cholangitis (PSC), described 
an odds ratio of 4.09 (95% CI, 2.89-5.76) when compared 
to UC patients without PSC.[24] This result has led to the 
recommendation of closer surveillance in this unique at-risk 
subset of UC patients. Furthermore, the location of colon 
cancer seen in PSC patients (right side predominant) should 
be carefully considered as this finding may help to influence 
the surveillance approach.
In conclusion, consistent data support the oncogenetic 
impact of chronic inflammation (and IBD, in particular) 
in colorectal mucosa. Thus the “adenoma–carcinoma” 
sequence of sporadic cancers becomes the “inflammation–
dysplasia-carcinoma” sequence in IBD. On a clinical level, 
the link between inflammation and IBD-related neoplasia 
relies on the well-known correlation between cancer risk and 
disease activity, extent, and duration.[25]
Among the risk factors examined in this literature review, 
the severity of inflammation appears to be the only 
modifiable risk factor, thus underscoring the importance of 
chemoprevention in mitigating cancer risk, and therefore the 
need for a preventive approach to the early detection of CRC.
The most recent meta-analysis of population-based studies 
associated UC with a 2.4-fold risk of CRC, which represents 
an overall 1.6% CRC rate (including sporadic cases) during 
the first 14 years of follow-up for UC patients.[26] Indeed, 
the declining trend in the incidence of CRC among UC 
patients gives the impression that combining the control 
of UC-related inflammation with surveillance strategies is 
highly effective in CRC secondary preventions and suggests 
that appropriate levels of vigilance should be maintained in 
high-risk patient populations.[25]
Crohn’s disease
The evaluation of the risk of CRC in CD poses several 
methodological challenges, related to the heterogeneous 
nature of the disease, with many patients having no colonic 
involvement, and considering that even among patients with 
Crohn’s colitis it is difficult to assess the extent of colonic 
inflammation, given that the disease can involve any area of 
the colon in a patchy distribution, and that many Crohn’s 
patients have undergone partial surgical resection of the colon, 
removing some of the at-risk tissue. This could justify the wide 
variation among the studies estimating the risk of CRC in CD.
Gyde and coworkers reported a relative risk (RR) of CRC 
in Crohn’s colitis of 23.8, whereas the risk was 4.3 in the 
general CD population,[27] whereas Greenstein and coworkers 
calculated an RR of 6.9 for developing CRC in isolated 
colonic CD.[28] Another study showed an RR of CRC of 5.6 
for those only with colonic involvement, as compared to an 
RR of 3.2 for patients with ileocolitis and 1.0 for patients 
with ileal involvement only.[29] These studies indicate that 
CD implies a higher risk of CRC, but also that this risk 
correlates with the extent of colonic involvement.
A meta-analysis of 12 hospital-based and population-based 
studies on CRC risk in CD revealed an overall RR of CRC 
in all the patients of 2.5  (95% CI, 1.3-4.7),[30] whereas 
in the subset of patients with colonic disease this risk 
rose to 4.5 (95% CI, 1.3-14.9), and for patients with ileal 
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disease only the risk was not significantly different from 
the general population. The cumulative risk of CRC for 
all patients with CD, regardless of disease distribution, 
was 2.9% after 10 years, 5.6% after 20 years, and 8.3% 
after 30 years of disease. This finding is in contrast to the 
Jess meta-analysis, which included population studies of 
intestinal cancer risk in CD,[31] where the estimation of 
RR of CRC ranged from 0.9 to 2.2, with a pooled estimate 
of 1.9 (95% CI, 1.4-2.5).
Gillen and coworkers compared the risk of CRC in patients 
with extensive Crohn’s colitis and in patients with extensive 
UC,[32] showing a cumulative risk of CRC of 8% at 22 years 
for patients with CD versus 7% at 22 years for patients 
with UC. With regard to the risk factors for CRC in CD, 
CD patients share many of the same risk factors for CRC 
as UC patients (ie, younger age at diagnosis, greater extent 
of colonic involvement, and longer duration of disease). 
Furthermore, bypassed segments of bowel[33] and perianal 
fistulae[34] in CD may also be sites at increased risk for 
carcinogenesis, just as bowel strictures may harbor dysplasia 
or cancer[35] and should be carefully biopsied and resected 
if a pediatric or upper endoscope cannot traverse them.
Actually it is really difficult to establish exactly the risk of 
CRC in CD, although it is generally accepted that patients 
with CD of the colon are at increased risk for dysplasia and 
CRC, and that this risk is related to the cumulative effect 
of colonic inflammation, as in UC. With the exception of 
strictures as mentioned above, screening and surveillance of 
CRC in patients with CD should be handled identically to 
patients with UC, matched for extent of colonic involvement.
In summary, the more recent studies mentioned above, 
which follow a more representative proportion of all patients 
with IBD,[13] demonstrates that the risk of CRC is lower 
than previously thought. Furthermore, the influence of 
time of disease seems to be much less significant and more 
important factors such as inflammatory burden and disease 
extent should guide the surveillance approach. Table 1 shows 
the confirmed risk factors and proposed protective factors 
for developing CRC in IBD patients and Table 2 shows the 
characteristics of the studies evaluating the risk factors for 
CRC in IBD patients.
SURVEILLANCE: THE PAST
Ideally, only a randomized controlled trial, with a very 
large number of patients and a long follow-up, could assess 
whether surveillance reduces CRC-related mortality. To date, 
only case-control studies have provided information about 
this topic. A Cochrane review[36] performed by Collins and 
coworkers revealed only three case-control studies, in the 
current literature, that addressed the question of whether 
surveillance programs reduce CRC-related mortality.[37-39] In 
the first one, Lashner and coworkers[37] found an improved 
overall survival but not a reduced mortality from CRC [RR, 
2.09; 95% CI, 0.39-11.12]. In the second one, Karlen and 
coworkers[38] reported a protective effect, although not 
statistically significant, of surveillance colonoscopy on 
CRC-related mortality. In fact two of the 40 patients who 
died from CRC had undergone at least one surveillance 
colonoscopy compared with 18 of the 102 controls (RR, 0.29; 
95% CI, 0.06-1.31). Only one patient who died from CRC had 
had at least two surveillance colonoscopies (RR, 0.22; 95% 
CI, 0.03-1.74), thus indicating a possible “dose”–response 
relationship. Finally, Choi and coworkers[39] showed that CRC 
in IBD patients undergoing surveillance is detected at an 
earlier stage (P = 0.039). The authors of the abovementioned 
meta-analysis concluded that there was indirect evidence for 
improved survival from colonoscopic surveillance.
The goal of colorectal cancer screening colonoscopy in the 
general population and surveillance in IBD patients is to 
detect premalignant changes early enough that intervention 
can prevent complications of invasive cancer. Dysplasia, 
assessed by histology, remains the most reliable marker of 
cancer-prone IBD patients.[25] Its detection depends on 
the timing of the endoscopic follow-up, on the endoscopic 
techniques employed during the follow-up, on the quality 
and the quantity of the biopsy samples obtained, on the 
endoscopist’s and pathologist’s expertise, and on the 
patient’s compliance with the recommended follow-up.[1,25] 
The mandatory operation in IBD-associated dysplasia is 
colectomy, because of the high prevalence of synchronous 
or metachronous cancer, as well as the technical limitations 
of being able to identify confidently and completely resect 
dysplastic lesions in flat mucosa.[40]
Table 1: The confi rmed risk factors and proposed 
protective factors for developing CRC in IBD patients
Confi rmed risk factors Proposed protective factors
Extent of colitis
UC pancolitis
UC left-sided colitis
CD colitis
5-ASA treatment
Disease duration UDCA treatment
Association with PSC Folate supplementation
Family history of CRC Maintainance of remission
Age at diagnosis Mucosal healing
Active infl ammation
Pseudopolyps
Strictures
Degree of infl ammation
Bypassed segments of bowel
CRC: Colorectal cancer, IBD: Infl ammatory bowel disease, OR: Odds 
ratio, LGD: Low-grade dysplasia, PSC: Primary sclerosing cholangitis, 
CI: Confi dence interval, HR: Hazard ratio, ASA: Acetylsalicylic acid, 
UDCA: Ursodeoxycholic acid
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Table 2: Summary of the characteristics of the studies evaluating the risk factors for CRC in IBD patients
Study (Author, year) Study design Prognostic factors 
for recurrence or 
progression of 
dysplasia or cancer
Frequency of 
surveillance
Population
Eaden et al. (2001) Meta-analysis of 116 
studies
Duration of disease
Extent of disease
- 24,478 people with ulcerative 
colitis 1698 with CRC
Jess et al. (2005) Meta-analysis of 6 
studies
Gender
Extent of disease
- 6538 people with Crohn’s disease 
55 with CRC
Soetikno et al. (2002) Meta-analysis of 11 
studies
PSC - 16,844 people with ulcerative 
colitis 564 with ulcerative colitis 
and PSC
560 with CRC, including 60 with 
ulcerative colitis and PSC
Thomas et al. (2007) Meta-analysis of 20 
studies
Displasia at diagnosis - Over 2677 people with ulcerative 
colitis 508 with LGD 31 with CRC
Askling et al. (2001) Retrospective 
(assumed) cohort, with 
nested case– control
Extent of disease
Family history
- 19,876 people with ulcerative 
colitis or Crohn’s disease 143 
with CRC
Brentnall et al. (1996) Prospective cohort Age at diagnosis
Duration of disease
PSC
- 45 people with ulcerative colitis 
20 with PSC 13 with dysplasia
Broome et al. (1992) Retrospective 
(assumed) cohort
Age at diagnosis
Duration of disease
PSC
- 72 people with ulcerative colitis 
5 with PSC 17 with dysplasia, 
carcinoma, and/or DNA 
aneuploidy
Broome et al. (1995) Retrospective 
(assumed) cohort
PSC - 120 people with ulcerative colitis 
40 with PSC and ulcerative colitis 
7 with CRC
D’Haens et al. (1993) Retrospective case–
control
Age at diagnosis
PSC
- 58 people with ulcerative colitis 
29 with PSC 9 with CRC
Ekbom et al. (1990) Retrospective 
(assumed) cohort
Gender
Age at diagnosis
Duration of disease
Extent of disease
- 1655 people with Crohn’s disease 
12 with CRC
Florin et al. (2004) Retrospective case–
control
PSC - 384 people with ulcerative colitis 
90 with PSC 8 with CRC
Friedman et al. 
(2001)
Retrospective 
(assumed) cohort
Age - 259 people with Crohn’s disease 
5 with CRC
Gilat et al. (1988) Prospective 
(assumed) cohort
Duration of disease - 1035 people with ulcerative colitis 
Number with CRC not reported
Gupta et al. (2007) Retrospective cohort Gender
Age at diagnosis
Duration of disease
Extent of disease
PSC
Severity of 
infl ammation
HR 1.7 (95% CI 0.9 to 3.0) 
for association of frequency 
of colonoscopy (1 or 
more per year) with any 
neoplasia HR 3.9 (95% CI 
1.3 to 11.4) for advanced 
neoplasia (univariate only)
418 people with ulcerative 
colitis 65 with any neoplasia 
15 progressed to advanced 
neoplasia
Gyde et al. (1988) Retrospective cohort Gender
Age at diagnosis
Duration of disease
Extent of disease
- 823 people with ulcerative colitis 
38 with CRC
Hendriksen et al. 
(1985)
Retrospective 
(assumed) cohort
Duration of disease
Extent of disease
- 783 people with ulcerative colitis 
7 with colonic cancer
Jess et al. (2006) Retrospective 
(assumed) cohort
Age at diagnosis
Type of IBD
Extent of disease PSC
Location of dysplasia
- 692 people with IBD 29 with 
colorectal dysplasia
(Contd...)
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IBD-CRC occurs in areas of chronic inflammation and can be 
a polypoid, ulcerated, or plaque-like lesion. Most IBD-CRCs 
are adenocarcinomas, but there is a higher incidence of 
poorly differentiated, anaplastic, and mucinous carcinomas 
compared with sporadic colorectal cancer.[40]
The best technique for surveillance is evolving. Currently, 
endoscopists are moving away from using random colonic 
biopsies toward targeted biopsies aimed at abnormal 
areas identified by newer colonoscopic techniques (chro 
moendoscopy, confocal microendoscopy, narrow band 
imaging). In this connection, although dysplasia has been 
shown to be highly predictive for cancer in many studies, 
the time-consuming process of multiple random biopsies 
and sometimes inconclusive pathology findings still form 
the basis for doubt among many gastroenterologists.
Furthermore, many studies have shown a low number of 
biopsies taken during surveillance, suggesting that this 
strategy is challenging to comply with.
The risk of IBD-CRC is estimated based on duration and extent 
of disease, coexistent risk factors (PSC, family history of sporadic 
CRC), and endoscopic and histological findings at colonoscopy. 
The surveillance intervals are based on this risk assessment.[42]
International guidelines recommend systematic surveillance 
in patients with a history of 8-10 years of extensive UC, 
In the general population, the dysplastic or premalignant 
lesion is the colon polyp that can be easily visualized and 
resected at the time of the colonoscopy before it transforms 
into a malignant lesion. In contrast, dysplasia in IBD can 
be found at sites distant from the cancer itself or before the 
cancer develops and is difficult to recognize on colonoscopy, 
as it often arises from flat, normal-appearing mucosa.[41]
IBD-related dysplasia usually presents with marked 
macroscopic variability. In fact it can be found, similar to 
flat dysplasia, in random biopsy specimens obtained from 
unremarkable mucosa; on the other hand, it can occur within 
or near plaque-like lesions or raised polypoid masses, defined 
as dysplasia-associated lesion or mass (DALM).
More recently, the definitions of adenoma-like mass 
or dysplasia  (ALM or ALD) have been proposed. ALM 
is applied to polypoid dysplasia with no adjacent flat 
component, endoscopically indistinguishable from a 
sporadic (sessile or pedunculated) polyp and completely 
removable by endoscopy; in this case, histology is of little 
help in differentiating DALM from ALM and this distinction 
basically relies on endoscopy.[25]
Because IBD-CRC is preceded by dysplasia, finding dysplasia 
on random colon biopsies represents an increased risk of 
developing colorectal cancer in the near future. Dysplasia is 
classified as indefinite, low-grade, and high-grade.
Table 2: Contd...
Study (Author, year) Study design Prognostic factors 
for recurrence or 
progression of 
dysplasia or cancer
Frequency of 
surveillance
Population
Jess et al. (2007) Retrospective 
(assumed) cohort, with 
nested case– control
PSC
Family history
Severity of 
infl ammation
Adjusted OR 5.3 (95% CI 
1.4 to 20) for colorectal 
neoplasia if one or more 
colonoscopic surveillances 
during the disease 
course compared with no  
surveillance
145 people with IBD 43 with 
neoplasia
Karlén et al. (1998) Retrospective cohort, 
with nested case–
control
- RR 0.29 (95% CI 0.06 
to 1.31) for risk of CRC 
mortality if colonoscopic 
surveillance ever compared 
with never. RR 0.43 (95% CI 
0.05 to 3.76) for risk of CRC 
mortality if one colonoscopic 
surveillance compared 
with never. RR 0.22 (95% 
CI 0.03 to 1.74) for risk of 
CRC mortality if two or more 
colonoscopic surveillances 
compared with never
142 people with ulcerative colitis 
40 with CRC (deaths)
 CRC: Colorectal cancer, IBD: Infl ammatory bowel disease, LGD: Low-grade dysplasia, PSC: Primary sclerosing cholangitis, OR: Odds ratio, 
CI: Confi dence interval, HR: Hazard ratio
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or 15 years of left-sided UC, whereas earlier surveillance 
is not recommended. Surveillance colonoscopies should 
be performed when the disease is in remission. The 
guidelines also recommend obtaining 2-4 random colon 
biopsy specimens every 10 cm with additional samples of 
any suspicious areas.[43-48] Table 3 shows the characteristics 
of the main studies on surveillance for CRC in IBD 
patients. Table 4 shows the main differences between 
the recommendations, arising from the international 
guidelines, for colorectal cancer surveillance programs in 
IBD patients.
ROLE OF THE PATHOLOGIST IN THE DETECTION 
OF DYSPLASIA AND COLORECTAL CANCER IN 
INFLAMMATORY BOWEL DISEASE
The detection of dysplasia and colorectal cancer in IBD depends, 
as mentioned above, on several variables: (1) the frequency 
of colonoscopy and the technique used; (2) the quality and 
quantity of the biopsy samples obtained; (3) the endoscopist’s 
and pathologist’s expertise; and (4) the patient’s compliance 
with the recommended follow-up.[1,25]
Histology in expert hands remain the most reliable way to 
identify cancer-prone cases  (dysplasia patients). In fact, 
after delivery of paraffin-embedded biopsy samples to the 
pathologist, the pathologist is concerned with the microscopic 
examination of the biopsy samples, the determination and 
classification of dysplasia, and the confirmation of the 
suspicions of the endoscopist. The histological assessment 
of biopsy specimens (from wherever they were obtained) is 
fundamental to patient’s management: It is ultimately the 
pathologist’s interpretation that distinguishes high-risk from 
low-risk patients and triggers recommendations to continue 
surveillance or opt for colectomy.[25]
However, the detection and the characterization of 
dysplasia has several well-recognized limitations, including 
its low intra- and inter-observer variability  (even among 
experts).[49,50]
In both prospective and retrospective studies, inter-observer 
consistency in the histological assessment of dysplasia 
has ranged between 42% and 72%.[51-57] Furthermore, Lim 
and coworkers[57] found a kappa coefficient between 10 
pairings of five gastrointestinal pathologists in the range of 
0.6  (acceptable) to 0.39  (unacceptable). Such agreement 
is naturally best when the two extremes of the histological 
spectrum of the lesions are considered (no dysplasia versus 
high-grade dysplasia), while the diagnostic consistency is worse 
when distinguishing between the intermediate categories.[41,58] 
Due to this lack of concordance, the international guidelines 
strongly recommended that dysplasia, as assessed prior of 
any surgical treatment, must be confirmed by a second, 
experienced gastrointestinal pathologist.[48,59,60]
SURVEILLANCE: THE PRESENT AND THE FUTURE
There have been recent advancements in optical methods 
and dye systems to more accurately detect dysplasia.
These techniques may allow for targeted biopsies and 
eliminate the need for random biopsies. The most promising 
technique to date and one that has been endorsed recently 
by the Crohn’s and Colitis Foundation of America Colon 
Cancer in IBD Study Group[48] is chromoendoscopy. In this 
technique, a dye such as methylene blue or indigo carmine 
is applied to the colon either randomly or selectively to 
highlight areas of dysplasia. Methylene blue is an absorptive 
dye that is taken up by normal tissue but not dysplastic tissue, 
and indigo carmine is a contrast dye that pools in areas of 
abnormal dysplastic tissue.
The pioneering studies performed by Kiesslich et al.[61] and 
Rutter et al.[62] have shown increased dysplasia detection with 
chromoendoscopy compared with conventional colonoscopy. 
Indeed, Rutter and coworkers[62] did not find any dysplasia 
in 2904 random biopsies utilizing conventional colonoscopy, 
while nine dysplastic lesions were detected in 157 targeted 
biopsies with indigo carmine chromoendoscopy, seven of 
which were only visible with dye spraying.
Table 3: Characteristics of the main studies on surveillance for CRC in IBD patients
Author (year) Choi et al. (1993) Lashner et al. (1990) Karlen et al. (1998)
Population People with ulcerative colitis of 
at least 8 years duration and 
extension of disease proximal to 
the sigmoid colon (n=50)
People with extensive ulcerative colitis (defi ned 
as continued disease from any point proximal 
to the splenic fl exure to the distal rectum) of at 
least 9 years’ duration (n=186)
People with extensive and longstanding 
ulcerative colitis (n=142)
Intervention Surveillance with biopsies every 
2 years (every 3 years in the 
early years of the programme) 
after negative results on two 
consecutive annual examinations
People had 4.2±3.0 (range 1–16) 
colonoscopies during the study period at a 
mean of 17.0 years after symptom onset
Two of 40 patients with UC and 18 of 
102 controls had undergone at least one 
surveillance colonoscopy. Twelve controls 
but only one patient with UC had undergone 
two or more surveillance colonoscopies
Comparator No surveillance No surveillance No surveillance
CRC: Colorectal cancer, IBD: Infl ammatory bowel disease, UC: Ulcerative colitis
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Table 4: Summary of the main differences between the recommendations arising from the international guidelines 
for colorectal cancer surveillance programmes in infl ammatory bowel disease patients
Guidelines Beginning of 
surveillance
Surveillance schedule Biopsy protocol New endoscopic 
technique recommended
U.K. 2002 8-10 yr (pancolitis)
15-20 yr (left-sided colitis)
3 yr (2nd decade)
2 yr (3rd decade)
1 yr (4th decade)
33+ Not mentioned
AGA 2010 8 yr (pancolitis)
15 yr (left-sided colitis)
Every 1-2 yr 33+ Not mentioned
ACG 2010 8-10 yr Every 1–2 yr 33+ Not yet
ECCO 2008 8 yr (pancolitis)
15 yr (left-sided colitis)
2 yr (1st–2nd decade)
−1 yr (3rd decade)
33+
If no chromoendoscopy
Chromoendoscopy
BSG 2010 10 yr −3 yr lower risk
−2 yr intermediate risk
−1 yr higher risk
33+
If no chromoendoscopy
Chromoendoscopy
German 
Guidelines 2010
8 yr (pancolitis)
15 yr (left-sided colitis)
Annually 33+ Not yet
U.K.: United Kingdom, AGA: American gastroenterology association, ACG: American college of gastroenterology, ECCO: European crohn’s and colitis 
organization, BSG: British society of gastroenterology
Successively, several studies have shown that chrom 
oendoscopy increases sensitivity for the detection of 
dysplasia. A recently published meta-analysis calculated a 
pooled incremental yield of chromoendoscopy over white 
light for dysplasia detection. The authors were able to find 
that in six studies on 1277 patients, chromoendoscopy was 
significantly better than white light for the detection of 
dysplasia in colonic IBD.[63]
In the technical review and position statement published by 
the AGA, the authors concluded that targeted biopsies using 
chromoendoscopy performed by endoscopists experienced 
in this technique is a reasonable screening alternative to the 
random sampling of colon using standard white light.[64,65]
In the AGA Institute technology assessment of image-enhanced 
endoscopy  (IEE), the authors concluded that IEE may 
increase the yield of detection of dysplasia and as such is 
recommended for patients with long-standing UC.[66]
Finally, The British Society of Gastroenterology (BSG) advises 
that all patients with IBD should have a screening colonoscopy 
approximately 10 years after symptom onset (ideally when 
the patient is in remission) with pancolonic dye spraying and 
targeted biopsies of abnormal areas.[42]
The surface guidelines for the application of chromoendoscopy 
in IBD patients with longstanding colitis and mucosal 
healing were developed to provide a better standardization 
of this technique.[67]
However, the use of surface dyes during chromoendoscopy 
in some cases has generated safety concerns. Prior in vitro 
biochemical studies have established that in the presence of 
light, methylene blue can generate single-strand breaks in 
DNA. As an alternative to methylene blue, indigo carmine 
is generally regarded as a safe dye because it is not absorbed 
by the colonic mucosa. To date, however, no long-term data 
exist that capture adverse clinical outcomes, and some groups 
continue to use methylene blue chromoendoscopy.[68]
Furthermore, chromoendoscopy presents multiple 
other potential limitations; the mucosa is not always 
equally sprayed, areas of colorant pooling prevent proper 
visualization, and, most importantly, it tends to be more 
time-consuming. It is also virtually impossible to perform 
chromoendoscopy in the context of poor colonic cleansing 
and in the presence of severe colonic inflammation where a 
neoplasia-like pit pattern is often seen, potentially producing 
false-positive results.[69]
With regard to the costs of the procedure the accessories 
needed to perform tissue staining are readily available and 
relatively inexpensive  (208 US dollars for the Olympus 
Reusable kit, 67 US dollars for the Wilson-Cook Medical 
single-use kit, and 225 US dollars for the Hobbs medical 
single-use kit). However, there is no specific Current 
Procedural Terminology  (CPT) code for billing and 
reimbursement for the time and effort added to the 
endoscopic procedure.
Other techniques that are currently under study but are 
not yet proved for widespread clinical use include confocal 
microendoscopy and narrow-band imaging.
Confocal laser endomicroscopy (CLE) allows imaging of the 
mucosal layer, including epithelial cells and the lamina propria. 
The targets of endomicroscopic examination for an accurate 
diagnosis can be the cells, vascular structures, and/or tissue 
patterns.[70] In addition, if an immediate diagnosis cannot be 
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obtained by CLE, the same technique offers the possibility 
of targeted biopsies. The pathologist will receive fewer biopsy 
specimens but will find more specific tissue because a greater 
number of “intelligent” biopsy specimens containing target 
tissue are provided by the endoscopist.[71]
Confocal endomicroscopy has been proposed as an addition 
to chromoscopically detected lesions to help target biopsies 
and reduce their number. In a study by Kiesslich and 
coworkers, chromoendoscopy reduced biopsies 10-fold. 
The addition of confocal could have reduced the number of 
biopsies a further fivefold to approximately one per patient. 
Although there is the possibility of having to perform very 
few biopsies, the technique is technically demanding and 
the instruments currently unwieldy.[72]
CLE is possible after injecting 2.5-5 mL fluorescein 10% 
intravenously. A confocal miniaturized laser with a defined 
wavelength of 488 nm generates in vivo histology images up 
to a 1000-fold magnification. During ongoing endoscopy, 
single cellular and subcellular tissue analyses 0-250 μm in 
depth are visible. In patients with UC, targeted biopsies of 
mucosal areas suspected of harboring intra-epitelial neoplasia 
can be identified directly while performing the colonoscopy.
The main limitation of CLE is that this technique is only 
limited to a very small mucosal surface; furthermore, the 
high costs of CLE (90,000 US dollars for the whole system) 
should be evaluated in a further cost-effectiveness analysis.
An alternative technique to CLE is the miniprobe-based 
endomicroscopy technique. After the miniprobe is passed 
through a 2.8-mm working channel of any standard 
videoendoscope, the laser unit generates a confocal image 
with a high frame rate per second. Special attention toward 
this technique has taken place since a high-resolution 
miniprobe device was developed.[72]
With regard to narrow band imaging  (NBI), there was 
great hope that NBI would be able to act as a form of 
“electronic chromoendoscopy” to make colitis surveillance 
more efficient. Unfortunately, probably due to background 
inflammation, dysplasia detection was no different to 
white light in two tandem studies and one multi-center, 
randomized, parallel group study.[73-75] Furthermore, 
recently a prospective, randomized crossover study was 
published to compare NBI and chromoendoscopy for the 
detection of intraepithelial neoplasia: NBI appears to be 
a less time-consuming and equally effective alternative to 
CE for the detection of intraepithelial neoplasia. However, 
given the NBI lesion and patient miss rates, the authors did 
not recommend it as the standard technique.[76] Similarly, 
a meta-analysis to determine whether use of NBI enhances 
the detection of adenomas, compared with conventional 
colonoscopy, was recently performed; there was no 
statistically significant difference in the overall adenoma 
detection rate with the use of NBI or WLC [36% vs. 34%; 
P = 0.413 (RR, 1.06; 95% CI, 0.97-1.16)], and there was no 
statistically significant difference in polyp detection rate by 
using NBI or WLC [37% vs. 35%; P = 0.289 (RR, 1.22; 95% 
CI, 0.85-1.76)).[77] For these reasons, it seems unlikely that 
NBI will be helpful for dysplasia detection in colitis.
The cost of NBI is 70,500 US dollars for the whole system 
(including endoscope, processor, and light source).
Endocytoscopy is a kind of reflecting light microscopy and the 
device is passed through a 3.7-mm working channel of any 
suitable endoscope. The magnification ranges from 450- to 
1100-fold depending on the device and the in vivo recognition 
of surface cells is possible after topically applying acylcysteine 
for mucolysis and methylene blue for staining. So far, there are 
no published data on this technique in patients with IBD.[78]
Some innovative endoscopy imaging techniques are under 
current evaluation to prove their eligibility for clinical routine 
endoscopy. Optical coherence tomography is an optical 
analogue to endoscopic ultrasound with an imaging depth 
of 2 mm. The device is also used in a “mother–baby fashion” 
through the working channel of the endoscope as mentioned 
above. There are two publications on this technique in 
patients with IBD.[79,80]
These studies have started to show the feasibility of this 
method and to differentiate transmural inflammation in 
CD from patterns of active UC.
Fluorescence endoscopy is a technique to assess intra-
epithelial neoplasia after topical or systemical sensitization 
with 5-aminolevulinic acid (5-ALA). After the application 
of 5-ALA, this substance is converted intracellularly into the 
fluophore protoporphyrin IX, which accumulates selectively 
in neoplastic tissue making it possible to detect a reddish spot 
while illuminated with blue monochromatic light (442 nm). 
The first report that evaluated fluorescence endoscopy 
in patients with UC was published in 2003.[81] This study 
examined 37 patients with UC and found a sensitivity of 
87%-100% after local application and 43% after systemic 
application with 5-ALA. The specificity was lower with 62% 
after systemic and 51% after local sensitization. However, 
3 years later another study could not confirm these results 
and evaluated 682 biopsies in 42 patients with IBD. The 
corresponding histology in two patients with intraepithelial 
neoplasia showed no correlation with the red fluorescent 
areas during fluorescence endoscopy.[82] However, neither 
optical coherence tomography nor fluorescence endoscopy 
is currently suitable for the detection of intraepithelial 
neoplasia in patients with IBD.
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Finally, in  vivo histology techniques are the basis for 
further diagnostic improvement on a single cellular 
level and have opened the door for molecular imaging 
in the gastrointestinal tract. There is one in vivo mouse 
model where colonic tissue samples are incubated with 
fluorescein-marked antibodies against epithelial growth 
factor receptor; in this mouse model a confocal microscope 
was able to detect the epithelial growth factor receptor 
on the surface of tissue after inducing colitis.[83] The first 
in vivo detection of dysplastic crypts by confocal microscopy 
in humans during ongoing endoscopy was possible after 
topical application of fluorescent-labeled heptapeptides, 
which were identified previously to bind to premalignant 
tissue as high-affinity ligands.[84]
FUTURE PERSPECTIVES
Because of the limitations of surveillance strategies 
based on the detection of dysplasia, further techniques 
involving the detection of alterations in mucosal antigens 
and genetic abnormalities are being investigated.[85,86] For 
example, it was shown that sialosyl-Tn is a mucin-associated 
carbohydrate antigen that may presage the development 
of dysplasia and CRC by several years.[87,88] Similarly, 
allelic deletions and point mutations of tumor suppressor 
genes, such as p53, Rb, mcc, and APC  (adenomatous 
polyposis coli) have been found in dysplastic and cancerous 
UC.[85,87,89]
It is likely that changes in nuclear DNA content are 
detectable earlier than histological signs of premalignancy. 
As a result, detection of DNA aneuploidy by flow 
cytometry of mucosal specimens in UC patients may 
be more objective and less sensitive to assessment 
error than dysplasia.[86] DNA aneuploidy detected by 
these techniques has been correlated with dysplasia 
and carcinoma.[90-92] However, as with dysplasia, the 
predictive value of aneuploidy is uncertain. Neoplasms 
can arise without preexisting aneuploidy, and conversely, 
aneuploidy may exist for many years without progression 
to malignancy.
Furthermore, stool-based molecular tests hold a large 
potential for improving colorectal cancer screening. Recent 
advances in the development of molecular markers in 
fecal specimens are encouraging for its use as a screening 
tool. Genetic mutations and epigenetic alterations that 
result from the carcinogenetic process can be detected by 
coprocytobiology in the colonocytes exfoliated from the 
lesion into the fecal matter. These markers have shown 
promising sensitivity and specificity in the detection of 
both malignant and premalignant lesions and are gaining 
popularity as a noninvasive technique that is representative 
of the entire colon.[93]
CONCLUSIONS
IBD shows an increased risk for developing CRC; in this 
setting, surveillance colonoscopy detects early neoplastic 
lesions and reduces colitis-associated mortality.
However, endoscopists are moving away from using random 
colonic biopsies toward targeted biopsies aimed at abnormal 
areas identified by advanced endoscopic imaging, when 
high-quality bowel cleansing and inactive mucosal disease 
are guaranteed.
Development of new biomarkers predicting future occurrence 
of colonic neoplasia may lead to a more biomarker-based 
surveillance. These are promising results that may lead to 
more efficient surveillance in IBD patients and more general 
acceptance of its employment.
Furthermore, the clinico-pathological link between IBD 
and CRC is well defined and provides the rationale for 
a differentiated endoscopic surveillance of patients with 
IBD without dysplasia, lesions indefinite for dysplasia 
or low-grade dysplasia, considering that patients with 
“late-onset” IBD should be considered “more prone” 
to cancer development. A multidisciplinary approach, 
together with a centralized patient management, could 
help to optimize treatments and follow-up measures, both 
of which could help to reduce the IBD-associated cancer 
risk (25). Therefore, physicians should apply into routine 
clinical practice:
• The simplification of dialogue between endoscopist and 
pathologist, to optimize patients’ management, together 
with
• The application of educational measures to improve 
patients’ awareness, thus optimizing the acceptance to 
both treatments and follow-up strategies.
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